Summary & Overview
HCPCS J9201: Gemcitabine Hydrochloride Injection, 200 mg
HCPCS Level II code J9201 denotes a 200 mg unit of gemcitabine hydrochloride for injection, an antineoplastic medication commonly administered intravenously in outpatient oncology settings. Nationally, this code is significant because it standardizes billing for a widely used chemotherapy agent across hospitals, cancer centers, and infusion clinics, enabling consistent reimbursement and utilization tracking for cancer care delivery.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for gemcitabine administration, typical sites of service, and the role of J9201 in drug billing. The publication summarizes payer coverage practices, benchmark rate context, and common billing considerations related to unitization and infusion-based chemotherapy products.
This piece provides practical reference material: what J9201 represents, how it is used in outpatient chemotherapy service lines, and what to expect from major national payers regarding coverage and claim processing. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9201 represents an injection of gemcitabine hydrochloride, specified as 200 mg per unit. This medication is an antineoplastic agent used in chemotherapy regimens for various solid tumors.
-
Service type: Intravenous chemotherapy administration (drug/product)
-
Typical site of service: Hospital outpatient infusion centers, oncology clinics, and outpatient chemotherapy infusion suites
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old female with metastatic pancreatic adenocarcinoma presenting to an outpatient oncology infusion center for scheduled chemotherapy. The oncologist orders intravenous gemcitabine hydrochloride dosed per body surface area, supplied and billed in 200 mg vial increments using J9201. The clinical workflow includes verification of the chemotherapy order, pre-treatment assessment (vital signs, toxicity review, laboratory checks such as complete blood count and liver function tests), pharmacist preparation of the dose in an aseptic compounding area, administration via peripheral IV or implanted port by an oncology nurse, monitoring for infusion-related reactions during and for at least 30 minutes after infusion, documentation of lot numbers and expiration dates for drug accountability, and recording of the administered dose and relevant modifiers on the claim. Typical sites of service are outpatient hospital infusion centers, physician office-based infusion suites, or ambulatory infusion centers. Common clinical reasons for use include treatment of solid tumors such as pancreatic, non–small cell lung, and bladder cancers, either as single-agent therapy or in combination regimens. Patient encounters may require modifier reporting for billed units, professional staffing, or circumstances such as inpatient admission, drug wastage, or discontinued administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/unused portion |